PMID- 16889084
OWN - NLM
STAT- MEDLINE
DCOM- 20060918
LR  - 20151119
IS  - 1728-2985 (Print)
IS  - 1728-2985 (Linking)
IP  - 3
DP  - 2006 May-Jun
TI  - [Comparative value of molecular forms of prostate-specific antigen in diagnosis 
      of prostatic cancer].
PG  - 21-4
AB  - The aim of the study was to compare diagnostic significance of free PSA 
      (fPSA)/total PSA (tPSA) versus PSA complex with alpha1-antichymotrypsin (cPSA) in 
      tPSA level within 4-10 ng/ml in differential diagnosis of prostatic cancer (PC). 
      A complete urological examination (digital rectal test, transrectal ultrasound 
      investigation, serum assay for fPSA and tPSA, multifocal transperineal prostatic 
      biopsy) was made in 108 patients with tPSA blood level 4-10 ng/ ml. Prostatic 
      adenoma (PA) was histologically verified in 61 of 108 patients, fPSA/tPSA was 
      normal. In the other 39 of 108 patients fPSA/tPSA was under 15% while cPSA was in 
      the range 3.8-9.6 ng/ml. A course of etiotropic therapy of chronic prostatic 
      inflammation produced no significant changes in fPSA/tPSA and cPSA in 28 out of 
      39 patients. Histologically, these 28 patients had PC. In the rest 11 of 39 
      patients chronic prostatitis treatment fPSA/tPSA significantly rose to 18.2%, on 
      the average. CPSA decreased to 2.4 ng/ml. These 11 patients were found 
      histologically to have PA and signs of chronic inflammation. In 8 of 108 patients 
      fPSA/tPSA was not indicative of PC being 18,2% on the average while cPSA 
      indicated the presence of PC and was 4.2 ng.ml, on the average. PC was verified 
      histologically in these 8 patients. Thus, cPSA in PC suspects is more informative 
      than fPSA/tPSA in PC diagnosis. CPSA in the serum depends on prostatic 
      inflammation making difficult differential diagnosis of PC in interpretation of 
      tPSA, fPSA/tPSA and cPSA. Therefore, estimation of PSA variants and molecular 
      forms in PC suspects and prostatic inflammation should be made after etiotropic 
      therapy.
FAU - Mazo, E B
AU  - Mazo EB
FAU - Sergeeva, N A
AU  - Sergeeva NA
FAU - Grigor'ev, M E
AU  - Grigor'ev ME
FAU - Lebedev, D V
AU  - Lebedev DV
FAU - Solov'eva, E V
AU  - Solov'eva EV
FAU - Konorev, V A
AU  - Konorev VA
FAU - Krovets, A A
AU  - Krovets AA
LA  - rus
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Urologiia
JT  - Urologiia (Moscow, Russia : 1999)
JID - 100900900
RN  - 0 (Antigens, Surface)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (NPSA protein, human)
RN  - 0 (alpha 1-Antichymotrypsin)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Antigens, Surface/*blood
MH  - Biomarkers, Tumor/*blood
MH  - Diagnosis, Differential
MH  - Humans
MH  - Male
MH  - Prostate-Specific Antigen/*blood
MH  - Prostatic Hyperplasia/diagnosis/pathology/therapy
MH  - Prostatic Neoplasms/*diagnosis/pathology/therapy
MH  - alpha 1-Antichymotrypsin/blood
EDAT- 2006/08/08 09:00
MHDA- 2006/09/19 09:00
CRDT- 2006/08/08 09:00
PHST- 2006/08/08 09:00 [pubmed]
PHST- 2006/09/19 09:00 [medline]
PHST- 2006/08/08 09:00 [entrez]
PST - ppublish
SO  - Urologiia. 2006 May-Jun;(3):21-4.